Youngsen Yang

Taitung, TNQ, Taiwan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

Multiplexed immunoassay for a serum autoantibody biomarker panel in diagnostic and prognostic prediction of canine mammary tumors.

Multiplexed immunoassay for a serum autoantibody biomarker panel in diagnostic and prognostic prediction of canine mammary tumors.

Journal: The veterinary quarterly

Published: December 06, 2024

Clinical outcomes of gastroenteropancreatic neuroendocrine neoplasms in Taiwan: A multicenter registry study-TCOG T1214 study.

Clinical outcomes of gastroenteropancreatic neuroendocrine neoplasms in Taiwan: A multicenter registry study-TCOG T1214 study.

Journal: Cancer

Published: November 06, 2024

AGR2-mediated unconventional secretion of 14-3-3ε and α-actinin-4, responsive to ER stress and autophagy, drives chemotaxis in canine mammary tumor cells.

AGR2-mediated unconventional secretion of 14-3-3ε and α-actinin-4, responsive to ER stress and autophagy, drives chemotaxis in canine mammary tumor cells.

Journal: Cellular & molecular biology letters

Published: December 25, 2023

Systemic treatments in pancreatic cancer: Taiwan pancreas society recommendation.

Systemic treatments in pancreatic cancer: Taiwan pancreas society recommendation.

Journal: Biomedical journal

Published: October 11, 2023

Clinical practice consensus for the diagnosis and management of melanoma in Taiwan.

Clinical practice consensus for the diagnosis and management of melanoma in Taiwan.

Journal: Journal of the Formosan Medical Association = Taiwan yi zhi

Published: October 26, 2022

The Implication of Serum Autoantibodies in Prognosis of Canine Mammary Tumors.

The Implication of Serum Autoantibodies in Prognosis of Canine Mammary Tumors.

Journal: Animals : an open access journal from MDPI

Published: August 13, 2022

Children with chronic myeloid leukaemia treated with front-line imatinib have a slower molecular response and comparable survival compared with adults: a multicenter experience in Taiwan.

Children with chronic myeloid leukaemia treated with front-line imatinib have a slower molecular response and comparable survival compared with adults: a multicenter experience in Taiwan.

Journal: British journal of cancer

Published: May 30, 2022

Comparison of molecular responses and outcomes between BCR::ABL1 e14a2 and e13a2 transcripts in chronic myeloid leukemia.

Comparison of molecular responses and outcomes between BCR::ABL1 e14a2 and e13a2 transcripts in chronic myeloid leukemia.

Journal: Cancer science

Published: May 04, 2022

Afatinib alone and in combination with vinorelbine or paclitaxel, in patients with HER2-positive breast cancer who failed or progressed on prior trastuzumab and/or lapatinib (LUX-Breast 2): an open-label, multicenter, phase II trial.

Afatinib alone and in combination with vinorelbine or paclitaxel, in patients with HER2-positive breast cancer who failed or progressed on prior trastuzumab and/or lapatinib (LUX-Breast 2): an open-label, multicenter, phase II trial.

Journal: Breast cancer research and treatment

Published: September 11, 2021

Trastuzumab emtansine (T-DM1) versus trastuzumab in Chinese patients with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy for HER2-positive breast cancer in the phase 3 KATHERINE study.

Trastuzumab emtansine (T-DM1) versus trastuzumab in Chinese patients with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy for HER2-positive breast cancer in the phase 3 KATHERINE study.

Journal: Breast cancer research and treatment

Published: September 11, 2020

Significant association of serum autoantibodies to TYMS, HAPLN1 and IGFBP5 with early stage canine malignant mammary tumours.

Significant association of serum autoantibodies to TYMS, HAPLN1 and IGFBP5 with early stage canine malignant mammary tumours.

Journal: Veterinary and comparative oncology

Published: June 18, 2020

Pertuzumab and trastuzumab as adjuvant treatment for HER2-positive early breast cancer: outcomes in Chinese patients in the APHINITY study.

Pertuzumab and trastuzumab as adjuvant treatment for HER2-positive early breast cancer: outcomes in Chinese patients in the APHINITY study.

Journal: Japanese journal of clinical oncology

Published: May 13, 2020

Showing 1-12 of 22

Last Updated: 09/26/2026